This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05648110
Recruitment Status : Recruiting
First Posted : December 13, 2022
Last Update Posted : September 6, 2023
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 7, 2023
Estimated Study Completion Date : January 21, 2025
CDC 2021 CDC (Centers for Disease Control and Prevention). General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: Accessed 23 May 2022.
Fact Sheet EUA Bebtelovimab 2022 US Food and Drug Administration. Fact Sheet For Healthcare Providers: Emergency Use Authorization for Bebtelovimab, March 2022. Available at: Accessed 23 May 2022.
NIH 2017 NIH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available at: Published 2017. Accessed 23 May 2022.
WHO 2020 World Health Organization. WHO COVID-19 Case definition, December 2020. Available at: Accessed 22 September 2022.
WHO 2022 WHO Coronavirus disease (COVID-19) dashboard. Available at: Accessed 09 September 2022.
CDC (Centers for Disease Control and Prevention). COVID-19. People who are immunocompromised. Available from: precautions/people-who-are-immunocompromised.html. Accessed 05 June 2023.